Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor–Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E–Deficient Mice
- 22 May 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (20) , 2495-2500
Abstract
Background —Atherosclerosis is characterized by an early inflammatory response involving proinflammatory mediators such as platelet-activating factor (PAF)-like phospholipids, which are inactivated by PAF-acetylhydrolase (PAF-AH). The effect of adenovirus-mediated expression of PAF-AH on injury-induced neointima formation and spontaneous atherosclerosis was studied in apolipoprotein E–deficient mice. Methods and Results —Intravenous administration of an adenovirus (5×10 8 plaque-forming units) directing liver-specific expression of human PAF-AH resulted in a 3.5-fold increase of plasma PAF-AH activity at day 7 ( P P PAF-AH –treated mice were similar to those of control virus-treated mice. Seven days after virus injection, endothelial denudation of the common left carotid artery was induced with a guidewire. Neointima formation was assessed 18 days later. PAF-AH gene transfer reduced oxidized lipoproteins by 82% ( P P =0.006), and smooth muscle cells by 84% ( P =0.002) in the arterial wall. This resulted in a 77% reduction ( P PAF-AH gene transfer reduced atherosclerotic lesions by 42% ( P =0.02) in male mice, whereas a nonsignificant 14% reduction was observed in female mice. Basal and PAF-AH activity after gene transfer were higher in male mice than in female mice ( P =0.01 and P =0.04, respectively). Conclusions —Gene transfer of PAF-AH inhibited injury-induced neointima formation and spontaneous atherosclerosis in apolipoprotein E–deficient mice. Our data indicate that PAF-AH, by reducing oxidized lipoprotein accumulation, is a potent protective enzyme against atherosclerosis.Keywords
This publication has 32 references indexed in Scilit:
- Sustained Expression of Human Apolipoprotein A-I after Adenoviral Gene Transfer in C57BL/6 Mice: Role of Apolipoprotein A-I Promoter, Apolipoprotein A-I Introns, and Human Apolipoprotein E EnhancerHuman Gene Therapy, 2000
- Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.Journal of Clinical Investigation, 1998
- The role of oxidized lipoproteins in atherogenesisFree Radical Biology and Medicine, 1996
- Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.Journal of Clinical Investigation, 1995
- Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.Journal of Clinical Investigation, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.Proceedings of the National Academy of Sciences, 1992
- Quantitation of plasma free cholesterol and cholesteryl esters by high performance liquid chromatography Study of a normal populationAtherosclerosis, 1989
- Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1988
- Inorganic and organic phosphate measurements in the nanomolar rangeAnalytical Biochemistry, 1987